Online citations, reference lists, and bibliographies.
← Back to Search

Botulinum Neurotoxin As A Therapeutic Modality In Orthopaedic Surgery: More Than Twenty Years Of Experience.

T. Seyler, B. Smith, D. R. Marker, J. Ma, J. Shen, T. Smith, Michael A Mont, Kat Kolaski, L. Koman
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Botulinum neurotoxins are among the most potent toxins found in nature, and are produced by Clostridium botulinum , an anaerobic, gram-positive, spore-forming rod-shaped bacterium1. There are seven known serotypes of botulinum neurotoxins (termed A, B, C1, D, E, F, G) that cleave soluble N-ethyl-maleimide-sensitive factor attachment receptor (SNARE) proteins, preventing effective release of neurotransmitters across specialized synaptic junctions. Blocking SNARE protein function within neuromuscular junctions produces flaccid paralysis, results in anhidrosis within sweat glands, and increases nutritional blood flow in vascular beds. On the basis of these findings, it was hypothesized that controlled injections of botulinum neurotoxins could be used to treat neuromuscular disorders. The benefits of botulinum neurotoxin injections in the treatment of various neurological disorders have captured the attention of physicians from multiple specialties and have contributed to the widespread use of botulinum neurotoxins in modern medicine2. Currently, only botulinum neurotoxin type-A (BoNT-A) and B (BoNT-B) serotypes are approved by the U.S. Food and Drug Administration. The mandated labeling includes the following therapeutic and anesthetic indications: (1) treatment of cervical dystonia in adults; (2) treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or seventh cranial nerve disorders in patients who are twelve years of age or older; (3) treatment of severe primary axillary hyperhidrosis; and (4) treatment of severe glabellar lines associated with corrugator and/or procerus muscle activity in patients who are sixty-five years of age or younger. This article outlines the role of botulinum toxins, particularly type A, as a therapeutic modality in musculoskeletal conditions on the basis of the peer-reviewed literature and the personal experience of the authors. Some of the information presented in this article describes off-label indications for drugs as defined by the Food and Drug Administration. The doses, side effects, techniques, and information reflect the …
This paper references
10.1097/01241398-199405000-00005
Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial.
L. Koman (1994)
10.1046/j.1468-1331.2001.00040.x
A randomized study of combined botulinum toxin type A and casting in the ambulant child with cerebral palsy using objective outcome measures
K. Desloovere (2001)
10.1016/J.FCL.2004.01.003
Clinical usefulness of botulinum toxin in the lower extremity.
Laura K Jacks (2004)
10.1002/mds.1282
Botulinum toxin and short-term electrical stimulation in the treatment of equinus in cerebral palsy.
C. Detrembleur (2002)
10.1017/S0012162201000020
Randomized controlled trial of physiotherapy in 56 children with cerebral palsy followed for 18 months.
E. Bower (2001)
10.1016/S0140-6736(05)62958-3
Treatment of chronic tennis elbow with botulinum toxin
Hhe Morré (1997)
10.1067/MPD.2000.108393
An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy.
D. Fehlings (2000)
10.1136/ADC.83.6.481
Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy.
T. Ubhi (2000)
10.1007/s00018-008-8088-0
Highly specific interactions between botulinum neurotoxins and synaptic vesicle proteins
A. Brunger (2008)
10.1111/j.1469-8749.2000.tb00056.x
Analgesic effects of botulinum toxin A: a randomized, placebo‐controlled clinical trial
S. Barwood (2000)
Shriners Hospital BTX-A Study Group. Comparing botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy
JD Ackman (2005)
10.1055/s-2006-942165
[Treatment of chronic plantar fasciitis with botulinum toxin A--an open pilot study on 25 patients with a 14-week-follow-up].
R. Placzek (2006)
Botulinum toxin type A injections for the management of flexion contractures following total knee arthroplasty.
T. Seyler (2008)
10.1097/01241398-199805000-00006
Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial.
I. Corry (1998)
10.1097/00004694-200411000-00006
Results of Zone II Flexor Tendon Repair in Children Younger Than Age 6 Years: Botulinum Toxin Type A Administration Eased Cooperation During the Rehabilitation and Improved Outcome
S. Tüzüner (2004)
10.1016/J.ARTH.2004.11.008
Flexion contracture after total knee arthroplasty in a patient with Parkinson's disease: successful treatment with botulinum toxin type A.
S. N. Shah (2005)
10.3310/HTA11160
Additional therapy for young children with spastic cerebral palsy: a randomised controlled trial.
A. M. Weindling (2007)
10.1097/00003086-198911000-00004
Rationale of the Knee Society clinical rating system.
J. Insall (1989)
10.7205/MILMED.171.7.653
Comparison of the efficacies of botulinum toxin A and Johnstone pressure splints against hip adductor spasticity among patients with cerebral palsy: a randomized trial.
Bulent Hazneci (2006)
10.1046/j.1468-1331.2001.00043.x
The effect of botulinum toxin type A and a variable hip abduction orthosis on gross motor function: a randomized controlled trial
R. Boyd (2001)
10.1097/01241398-199307000-00013
Management of Cerebral Palsy with Botulinum‐A Toxin: Preliminary Investigation
L. Koman (1993)
Effect of botulinum toxin type A on gait of children who are idiopathic toe-walkers.
D. Brunt (2004)
10.1542/peds.2007-0016
Botulinum Toxin for Spasticity in Children With Cerebral Palsy: A Comprehensive Evaluation
K. Bjornson (2007)
10.1097/BLO.0b013e31802c9098
How to Write a Systematic Review
R. Wright (2007)
10.1097/00003086-200208000-00015
Botulinum Toxin Injection Versus Surgical Treatment for Tennis Elbow: A Randomized Pilot Study
S. B. Keizer (2002)
10.2106/JBJS.D.01896
Botulinum toxin injection in the treatment of tennis elbow. A double-blind, randomized, controlled, pilot study.
M. Hayton (2005)
10.1111/j.1469-8749.2002.tb00328.x
Double‐blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy
F. Polak (2002)
10.1046/j.1468-1331.2001.00038.x
The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia a randomized controlled trial
S. Love (2001)
10.1002/mds.1282
Botulinum toxin and short‐term electrical stimulation in the treatment of equinus in cerebral palsy
C. Detrembleur (2002)
Treatment of lateral epicondylitis with botulinum toxin: a randomized, double-blind, placebo-controlled trial.
S. Wong (2005)
10.1080/00016470410001538
Selective botulinum toxin injection in the treatment of recurrent deformity following surgical correction of club footA preliminary report of 3 children
P. Mitchell (2004)
10.1097/01241398-200203000-00005
Technique for Iliopsoas Ultrasound-Guided Active Electromyography-Directed Botulinum A Toxin Injection in Cerebral Palsy
Michael J Willenborg (2002)
Longitudinal examination of health outcomes associated with botulinum toxin use in children with cerebral palsy.
R. Balkrishnan (2004)
10.1097/01253086-200024030-00015
Botulinum Toxin A in the Management of Spastic Gait Disorders in Children and Young Adults with Cerebral Palsy: A Randomized, Double-Blind Study of “High-Dose” versus “Low-Dose” Treatment.
Phyllis Guarrera-Bowlby (2000)
10.1016/S0966-6362(99)00012-0
Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy.
D. Sutherland (1999)
10.1097/00002508-200211001-00002
Therapeutic Use of Botulinum Toxins: Background and History
P. Setler (2002)
Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group.
L. Koman (2000)
10.2106/JBJS.F.00401
Treatment of chronic radial epicondylitis with botulinum toxin A. A double-blind, placebo-controlled, randomized multicenter study.
R. Placzek (2007)
10.1136/ard.2005.035840
Treatment of chronic plantar fasciitis with botulinum toxin A: an open case series with a 1 year follow up
R. Placzek (2005)
Evaluating the effects of ice application on the pain felt during botulinum toxin type-A injections: a prospective, randomized, single-blind controlled trial
N Sarifakioglu (2004)
10.1007/978-3-642-28753-4_101584
The Oswestry low back pain disability questionnaire.
J. Fairbank (1980)
10.3310/HTA11520
A review and critique of modelling in prioritising and designing screening programmes.
J. Karnon (2007)
10.1016/J.CLINDERMATOL.2003.11.009
Commercial preparations and handling of botulinum toxin type A and type B.
J. Parish (2003)
10.2106/00004623-198062030-00004
The development of mature gait.
D. Sutherland (1980)
10.1111/j.1469-8749.2005.tb01215.x
Comparing botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy
J. Ackman (2005)
10.1016/J.APMR.2006.10.017
Functional outcomes of intramuscular botulinum toxin type a and occupational therapy in the upper limbs of children with cerebral palsy: a randomized controlled trial.
M. Wallen (2007)
10.1046/j.1440-1754.1999.00330.x
Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy
P. Flett (1999)
10.1053/EJPN.2000.0445
Mouse gene knockout models for the CLN2 and CLN3 forms of ceroid lipofuscinosis.
M. Katz (2001)
10.1111/j.1469-8749.2005.tb01173.x
Botulinum toxin A and upper limb functional skills in hemiparetic cerebral palsy: a randomized trial in children receiving intensive therapy
L. Speth (2005)
10.1055/S-2007-973475
Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of "high-dose" versus "low-dose" treatment.
J. Wissel (1999)
10.1111/j.1469-8749.2002.tb00268.x
Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double‐blind, placebo‐controlled, dose‐ranging study
R. Baker (2002)
10.1017/S0012162206000041
Treatment of adductor spasticity with BTX‐A in children with CP: a randomized, double‐blind, placebo‐controlled study
V. Mall (2006)
10.2106/00004623-200411000-00003
Botulinum toxin as an adjunct to serial casting treatment in children with cerebral palsy.
R. Kay (2004)
10.2106/JBJS.G.00563
Early results of the Ponseti method for the treatment of clubfoot in distal arthrogryposis.
S. Boehm (2008)
10.1097/01.sap.0000139563.51598.75
Evaluating the Effects of Ice Application on the Pain Felt During Botulinum Toxin Type-A Injections: A Prospective, Randomized, Single-Blind Controlled Trial
N. Sarıfakioğlu (2004)
10.1097/00130911-199703000-00006
Applications of botulinum toxin in orthopedics and upper extremity surgery.
Van Heest Ae (1997)
10.1097/00005650-198004000-00010
The development of an impact-on-family scale: preliminary findings.
R. Stein (1980)
10.1016/S0140-6736(86)92070-2
DOUBLE-BLIND STUDY OF BOTULINUM TOXIN IN SPASMODIC TORTICOLLIS
J. C. Tsui (1986)
10.1302/0301-620X.49B4.695
Congenital short tendo calcaneus.
J. Hall (1967)
10.1177/000992289403300708
The Functional Independence Measure for Children (WeeFIM)
M. Msall (1994)
10.1111/j.1469-8749.1997.tb07408.x
Botulinum toxin A in the hemiplegia upper limb: a double‐blind trial
I. S. Corry (1997)
10.1097/01.PHM.0000160006.51859.AE
Botulinum Toxin Treatment of Spastic Equinus in Cerebral Palsy: A Randomized Trial Comparing Two Injection Sites
H. Sätilä (2005)
10.1097/01.PEP.0000087844.27971.50
Functional outcome of botulinum toxin A injections to the lower limbs in cerebral palsy,
T. Carey (2003)
Development of botulinum toxin therapy.
N. Hermanowicz (1995)
10.1097/BPO.0b013e31815b4d7d
A Pilot Study of Delayed Versus Immediate Serial Casting After Botulinum Toxin Injection for Partially Reducible Spastic Equinus
C. J. Newman (2007)
10.1097/01.bpo.0000149861.50400.db
Treatment of Idiopathic Clubfoot Utilizing Botulinum A Toxin: A New Method and its Short-term Outcomes
C. Alvarez (2005)
10.1097/00001577-200107000-00007
Botulinum toxin type a neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial.
C. Pieper (2001)
10.1016/J.PEDIATRNEUROL.2006.09.010
Effect of multilevel botulinum toxin a and comprehensive rehabilitation on gait in cerebral palsy.
V. Scholtes (2007)
10.1055/S-2006-942165
Behandlung der chronischen Plantarfasziitis mit Botulinumtoxin A - Eine offene Pilotstudie an 25 Patienten mit einem Beobachtungszeitraum über 14 Wochen
R. Placzek (2006)
10.1111/j.1469-8749.2007.00331.x
A randomized controlled trial comparing botulinum toxin A dosage in the upper extremity of children with spasticity
Anne Kawamura (2007)
10.1097/01.phm.0000176339.73591.d7
Treatment of Pain Attributed to Plantar Fasciitis with Botulinum Toxin A: A Short-Term, Randomized, Placebo-Controlled, Double-Blind Study
Mary S. Babcock (2005)
Compar - ing botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy
JD Ackman (2005)
Applications of botulinum toxin in orthopedics and upper extremity surgery.
A. V. Van Heest (1997)
Botulinum toxin type A injections for the management of flexion contractures following total A Seyler.fm Page 143 Wednesday
TM Seyler (2008)
Long-term effect of botulinum toxin (A) in the management of calf spasticity in children with diplegic cerebral palsy.
Z. Hawamdeh (2007)
10.1093/RHEUMATOLOGY/22.2.73
Lateral humeral epicondylitis--a study of natural history and the effect of conservative therapy.
A. Binder (1983)
10.1016/s0140-6736(64)90358-7
PHENOTHIAZINE DYSKINESIA AFTER LEUCOTOMY.
Bourdillon Jf (1964)
Doubleblind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy
DH Sutherland (1999)
10.1017/S0012162203001403
Botulinum toxin with and without casting in ambulant children with spastic diplegia: a clinical and functional assessment.
M. Bottos (2003)
10.1093/AJE/KWJ325
Prevalence and determinants of lateral and medial epicondylitis: a population study.
R. Shiri (2006)
10.1055/S-2003-43549
Treatment of lateralisation and subluxation of the hip in cerebral palsy with Botulinum toxin A: preliminary results based on the analysis of migration percentage data.
R. Placzek (2004)
10.1111/j.1469-8749.2007.00823.x
Repeat injection of botulinum toxin A is safe and effective for upper limb movement and function in children with cerebral palsy
K. Lowe (2007)
Treatment of iliopsoas tendinitis after a left total hip arthroplasty with botulinum toxin type A.
D. Fish (2007)
10.1007/bf00180221
Tennis elbow. Anatomical, epidemiological and therapeutic aspects.
J. Verhaar (1994)
10.1097/00004694-200007000-00021
A preliminary report of the use of botulinum toxin type A in infants with clubfoot: four case studies.
M. Delgado (2000)
10.2106/JBJS.F.01416
Does botulinum toxin a combined with bracing prevent hip displacement in children with cerebral palsy and "hips at risk"? A randomized, controlled trial.
H. Graham (2008)
10.1097/00001577-199801020-00013
Botulinum Toxin A in the Hemiplegic Upper Limb: A Double‐blind Trial
L. Arens (1997)
10.1053/ejpn.2000.0406
Book ReviewBook Reviews: Normal and Pathologic Development of the Human Brain and Spinal Cord
G. Cioni (2001)
10.1046/j.1468-1331.2001.00041.x
Single event multilevel botulinum toxin type A treatment and surgery: similarities and differences
G. Molenaers (2001)
10.1542/peds.2006-2425
Upper-Limb Botulinum Toxin A Injection and Occupational Therapy in Children With Hemiplegic Cerebral Palsy Identified From a Population Register: A Single-Blind, Randomized, Controlled Trial
R. Russo (2007)



This paper is referenced by
10.1016/j.jhsa.2020.06.008
Outcomes of Botulinum Toxin Injection for Shoulder Internal Rotation Contractures in Infants with Brachial Plexus Birth Injury.
A. Singh (2020)
10.1155/2012/898924
Effectiveness and Safety of Botulinum Toxin Type A in Children with Musculoskeletal Conditions: What Is the Current State of Evidence?
N. Dahan-Oliel (2012)
10.1155/2013/416246
Tendon Interposition and Ligament Reconstruction with ECRL Tendon in the Late Stages of Kienböck's Disease: A Cadaver Study
Nazım Karalezli (2013)
10.1155/2017/2957941
The Effect of Botulinum Toxin Type A on Expression Profiling of Long Noncoding RNAs in Human Dermal Fibroblasts
Y. Miao (2017)
10.1007/s00256-010-0897-1
Botulinum toxin injection in neurogenic thoracic outlet syndrome: results and experience using a ultrasound-guided approach
M. Torriani (2010)
10.1007/s12306-017-0515-7
The utility of botulinum toxin A in the repair of distal biceps tendon ruptures
L. S. Khalil (2017)
10.17169/refubium-4833
Doppelblinde, placebokontrollierte, randomisierte und multizentrische Studie zurWirksamkeit und Sicherheit einer einmaligen Injektion von Botulinumtoxin A zurBehandlung der chronischen Plantarfasziitis
A. Hölscher (2012)
10.1007/s11832-015-0633-4
Early ultrasonographic evaluation of idiopathic clubfeet treated with manipulations, casts, and Botox®: a double-blind randomized control trial
A. Howren (2015)
10.1007/978-3-319-34226-9_15
Capitate Shortening for Kienböck’s Disease
A. Afshar (2016)
10.5114/aoms.2014.46217
The effects of botulinum toxin type A on improvement and dynamic spastic equinus correction in children with cerebral palsy – preliminary results
H. Čolović (2014)
10.1007/978-1-4419-7692-5_19
Medical and Personal Care Applications of Bacteriocins Produced by Lactic Acid Bacteria
L. Dicks (2011)
10.1111/j.1524-4725.2012.02504.x
The Potential Effect of Botulinum Toxin Type A on Human Dermal Fibroblasts: An In Vitro Study
Sang-Ha Oh (2012)
10.1177/1071100712460215
A Comparison of Botulinum Toxin A and Intralesional Steroids for the Treatment of Plantar Fasciitis
Jorge Elizondo-Rodríguez (2013)
Neurological mechanisms underlying rotator cuff skeletal muscle pathophysiology and implications for therapy
Sandeep Mannava (2012)
10.1097/BPO.0000000000000398
Safety and Efficacy of Botulinum Toxin A in Children Undergoing Lower Limb Lengthening and Deformity Correction: Results of a Double-blind, Multicenter, Randomized Controlled Trial
R. Hamdy (2016)
10.2519/jospt.2010.0409
Kienbock's disease.
Shaun J O'Laughlin (2010)
Resultados funcionales de la aplicación de toxina botulínica tipo A contra antiinflamatorios orales en la rehabilitación de síndrome de hombro doloroso por lesión del mango de los rotadores
P. Becerril-Bautista (2014)
10.1016/j.jse.2020.02.026
Treatment methods for post-traumatic elbow stiffness caused by heterotopic ossification.
Christina E. Freibott (2020)
10.3390/toxins4080605
Botulinum Neurotoxin A Injections Influence Stretching of the Gastrocnemius Muscle-Tendon Unit in an Animal Model
P. Haubruck (2012)
10.1097/AJP.0b013e31823ae65a
Is Botulinum Toxin A Effective for the Treatment of Plantar Fasciitis?
Christian-Dominik Peterlein (2012)
10.2106/JBJS.L.00334
Magnetic resonance imaging of the hand and wrist: techniques and spectrum of disease: AAOS exhibit selection.
Ashvin K. Dewan (2013)
10.1142/S0218810411005436
Arthroscopic assisted bone grafting for early stages of Kienböck's disease.
L. Pegoli (2011)
10.1016/j.jhsa.2011.07.011
Recent advances for the management of Raynaud phenomenon using botulinum neurotoxin A.
S. Mannava (2011)
10.1177/1071100720961093
Comparison of Botulinum Toxin A, Corticosteroid, and Anesthetic Injection for Plantar Fasciitis.
Jorge Elizondo-Rodríguez (2020)
Effect of botulinum neurotoxin type A (BoNTA) on the morphology and viability of 3T3 murine fibroblasts.
C. Bandala (2015)
10.3928/01477447-20090818-29
Botulinum toxin type A in the treatment of painful adductor muscle contracture after total hip arthroplasty.
A. Santamato (2009)
10.1016/B978-0-12-227030-7.90001-5
Authors
Steven Shuangge (2010)
10.1016/j.jhsa.2010.11.014
Chemical denervation with botulinum neurotoxin a improves the surgical manipulation of the muscle-tendon unit: an experimental study in an animal model.
S. Mannava (2011)
10.4103/ijpn.ijpn_3_18
Plantar fasciitis: A review
N. Menon (2018)
10.1155/2016/3853754
The Efficacy and Safety of Fractional CO2 Laser Combined with Topical Type A Botulinum Toxin for Facial Rejuvenation: A Randomized Controlled Split-Face Study
J. Zhu (2016)
10.1016/j.jphotobiol.2014.03.009
Anti-photoaging potential of Botulinum Toxin Type A in UVB-induced premature senescence of human dermal fibroblasts in vitro through decreasing senescence-related proteins.
Felicia Permatasari (2014)
10.1503/cmaj.090906
Use of anatomic measurement to guide injection of botulinum toxin for the management of chronic lateral epicondylitis: a randomized controlled trial
R. Espandar (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar